CSL (CSLLY) Cash per Share: $0.59 (As of Dec. 2025)

What is CSL Cash per Share?

CSL CSLLY +6.37% 73 Cash per Share is $0.59 as of Dec. 2025. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.55 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). CSL's Cash per Share for the quarter that ended in Dec. 2025 was $0.59.

CSL (OTCPK:CSLLY) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

CSL Cash per Share Related Terms

CSL Cash per Share Historical Data

* Premium members only.

The historical data trend for CSL's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL Cash per Share Chart

CSL Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Cash per Share

Get a 7-Day Free Trial

0.99

5.42

0.80

0.86

1.11

CSL Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Jun25	Dec25
Cash per Share	Get a 7-Day Free Trial															0.80	0.53	0.86	1.11	0.59

73GF Score

CSL Ltd CSLLY

Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CSL Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

CSL's Cash per Share for the fiscal year that ended in Jun. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	2157	/	1,937
	=	1.11

CSL's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	1145	/	1,929
	=	0.59

Frequently Asked Questions Learn more about Cash per Share →

What does a Cash per Share of $0.59 mean?

CSL (CSLLY) has a Cash per Share of $0.59 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for CSL and its competitors.

Is CSL's Cash per Share too high?

CSL's current Cash per Share is $0.59. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does CSL's Cash per Share compare to VRTX and REGN?

CSL's Cash per Share of $0.59 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash per Share for a Biotechnology company?

A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash per Share mean?

A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for CSL and its competitors. CSL's current Cash per Share is $0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CSL stock overvalued right now?

Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.55, compared to a current price of $21.79 — trading 56.9% below its estimated fair value. The current Cash per Share is $0.59. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash per Share calculated?

Cash per Share is calculated from a company's financial statements. For CSL (CSLLY), the current Cash per Share is $0.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (CSLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of $21.79 is trading 56.9% below its estimated GF Value™ of $50.55. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for CSLLY:

Cash per Share: $0.59
GF Value™: $50.55 vs. price of $21.79 (56.9% below fair value)
GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:TLX ASX:MSB ASX:NEU ASX:PYC ASX:CU6 ASX:CUV ASX:RAC ASX:TTX ASX:SPL ASX:OCC VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ONC MRNA XKRX:068270

Other Exchanges CMXHF:USA CSJ:Germany CSL:Australia

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000

Website https://www.csl.com

CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

73GF Score

Get the complete analysis for CSLLY

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.79

Price

$50.55

GF Value

View CSLLY Analysis

See Cash per Share data for all stocks →